Cholesterol - the devil you know; ceramide - the devil you don't

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Metabolic Disease Research

Background:

• Ectopic lipids, including cholesterol and ceramides, are implicated in pathologies such as heart disease, stroke, and diabetes.
• Cholesterol is a well-established biomarker and therapeutic target for cardiovascular disease, with extensive research supporting statin interventions.
• Emerging evidence highlights ceramides as independent biomarkers and potential causative agents in human cardiometabolic diseases.

Purpose of the Study:

• To review the evidence supporting ceramide-targeting therapeutics for cardiometabolic diseases.
• To contrast the therapeutic potential of ceramides with established cholesterol-lowering strategies.

Main Methods:

• Literature review of studies on ectopic lipids, cholesterol, and ceramides in cardiometabolic disease.
• Analysis of rodent studies demonstrating the causative role of ceramides and the efficacy of their reduction.
• Comparison of existing data for cholesterol-based pharmaceuticals with emerging data for ceramide-based therapies.

Main Results:

• Ceramides are cholesterol-independent biomarkers for heart disease and diabetes.
• Rodent studies indicate that reducing ceramides prevents cardiovascular disease and diabetes.
• Therapeutics targeting ceramides show potential for treating cardiometabolic diseases.

Conclusions:

• Ceramides represent a novel and promising therapeutic target for cardiometabolic diseases.
• Targeting ceramides offers a distinct approach compared to cholesterol-focused interventions.
• Further research into ceramide-based therapies could lead to new treatments for heart disease and diabetes.